Table 2.
ECMO run characteristics
| All patients (n = 121) |
Bleeding group (n = 35) |
Non-bleeding group (n = 86) |
p value | |
|---|---|---|---|---|
| Indication, n (%) | 0.8 | |||
| Cardiogenic shock | 47 (39) | 13 (37) | 34 (39) | |
| Refractory cardiac arrest | 18 (15) | 6 (17) | 12 (14) | |
| ARDS | 41 (34) | 13 (37) | 28 (33) | |
| Intoxication | 15 (12) | 3 (9) | 12 (14) | |
| Type | 0.4 | |||
| Veno-venous | 44 (36) | 14 (40) | 30 (35) | |
| Veno-arterial | 77 (64) | 21 (60) | 56 (65) | |
| Cannula insertion | 0.4 | |||
| Femoro-femoral | 74 (61) | 21 (60) | 53 (61) | |
| Femoro-jugular | 41 (34) | 14 (40) | 27 (31) | |
| Subclavian | 4 (3) | 0 (0) | 4 (5) | |
| AVALON dual-lumen cathetera | 2 (2) | 0 (0) | 2 (3) | |
| Implantation day | ||||
| SOFA score | 11 [8–13] | 11 [8–13] | 12 [8–14] | 0.6 |
| Glasgow coma scaleb | 14 [3–15] | 14 [3–15] | 14 [3–15] | 0.8 |
| Hemoglobin (g/dL) | 11.5 [9.8–14.1] | 11.8 [9.9–14.0] | 11.2 [9.2–14.2] | 0.7 |
| Prothrombin ratio (%) | 73 [60–87] | 74 [58–91] | 72 [60–86] | 0.7 |
| Platelets (G/mm3) | 230 [170–303] | 233 [199–309] | 223 [160–288] | 0.4 |
| Creatininemia (µmol/L) | 106 [79–154] | 106 [79–148] | 109 [82–160] | 0.5 |
| During ECMO support | ||||
| Maximum creatininemia (µmol/L) | 153 [97–255] | 160 [110–224] | 145 [89–267] | 0.4 |
| Maximum bilirubinemia (µmol/L) | 20 [13–35] | 24 [14–32] | 20 [12–38] | 0.9 |
| Associated IABP / IMPELLAb, n (%) | 29 (24) | 15 (43) | 14 (16) | 0.004 |
| Associated RRT, n (%) | 40 (33) | 12 (34) | 28 (33) | 0.9 |
| Length of ECMO support (days) | 6 [3–10] | 8 [4–13] | 5 [3–9] | 0.03 |
Data reported as number (percentage) or median [interquartile range]
ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; SOFA, sequential organ failure assessment; RRT, renal replacement therapy
aAVALON Elite Bi-Caval Dual Lumen Catheter, Getinge, Sweden
bIMPELLA, Abiomed Europe, Germany